Discovery Laboratories, Inc.  

(Public, NASDAQ:DSCO)   Watch this stock  
Find more results for Michael Miller, Esquire
-0.06 (-3.06%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.88 - 1.96
52 week 1.50 - 3.05
Open 1.93
Vol / Avg. 663,795.00/772,968.00
Mkt cap 160.92M
P/E     -
Div/yield     -
EPS -0.79
Shares 84.70M
Beta 1.36
Inst. own 63%
Jun 10, 2014
Discovery Laboratories Annual Shareholder Meeting - 8:00AM EDT - Add to calendar
May 5, 2014
Q1 2014 Discovery Laboratories Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 Discovery Laboratories Earnings Conference Call
Mar 13, 2014
Q4 2013 Discovery Laboratories Earnings Release
Mar 11, 2014
Discovery Laboratories at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -20373.33% -19135.90%
Operating margin -18021.67% -19394.36%
EBITD margin - -18804.62%
Return on average assets -170.43% -172.49%
Return on average equity -439.91% -394.51%
Employees 105 -
CDP Score - -


Suite 100, 2600 Kelly Road
WARRINGTON, PA 18976-3622
United States - Map
+1-215-4889300 (Phone)
+1-215-4889301 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Discovery Laboratories, Inc. is a biotechnology company focused on creating life-saving products for critical care patients with respiratory disease. The Company�s produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. In addition, its capillary aerosol-generating technology produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 surfactant to the lung. It is developing its products, Surfaxin(lucinactant), Surfaxin LS and Aerosurf, to address the respiratory conditions affecting neonatal populations. It has filed a New Drug Application (NDA) for its product based on its KL4 surfactant technology, Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. It focuses on manufacturing three additional Surfaxin batches for use in the preclinical program.

Officers and directors

John R. Leone Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
John G. Cooper CPA President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
John A. Tattory Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Thomas F. Miller PhD Chief Operating Officer, Senior Vice President
Age: 42
Bio & Compensation  - Reuters
Mary B. Templeton Esq Senior Vice President, General Counsel and Corporate Secretary
Age: 66
Bio & Compensation  - Reuters
Kathryn A. Cole Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Russell Clayton Senior Vice President - Research and Development
Age: 52
Bio & Compensation  - Reuters
Thomas C. Hoy Vice President - Manufacturing Operations
Age: 52
Bio & Compensation  - Reuters
Michael L. Magee Vice President - Quality Operations
Age: 52
Bio & Compensation  - Reuters
William C. Roberts Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters